Melanin-concentrating hormone (MCH), a cyclic 19-aminoacid polypeptide, is produced predominantly by neurons in the lateral hypothalamus and zona incerta which project broadly throughout the brain 1 . Several lines of evidence implicate MCH as an important mediator in the regulation of energy balance and body weight. Central MCH administration stimulates food intake while fasting results in an increase in MCH expression 2 . Mice lacking the gene encoding MCH are lean, hypophagic and maintain elevated metabolic rates 3 . In contrast, mice overexpressing the MCH gene are susceptible to obesity and insulin resistance 4 . Although these findings support a rationale for MCH antagonists in the treatment of obesity, it is unclear if sufficient MCH tone exists to produce a robust and sustained loss of body weight after chronic MCH-receptor blockade. Moreover, because genetic manipulation of the MCH gene also affects the expression of neuropeptide E-I and neuropeptide G-E, which are processed from the same prehormone precursor as MCH, the observed phenotypes may be influenced by changes in the levels of these less characterized peptides 5 . The effects of MCH are mediated through receptors in the rhodopsin superfamily of G protein-coupled receptors (GPCRs). MCH1 receptor (MCH1-R) has been isolated from rodents and humans 6,7 , whereas MCH2-R has thus far been identified only in humans 8, 9 . To assess the role of MCH1-R, we identified a selective, high-affinity MCH1-R antagonist and evaluated it in several animal models. We report here that the acute administration of a MCH1-R antagonist attenuated central MCH-stimulated food intake, and reduced consumption of palatable food. Moreover, chronic administration of this antagonist produced a robust and sustained decrease in body weight in rats with diet-induced obesity. As the distribution of MCH1-R binding sites in the central nervous system (CNS) is suggestive of a role for MCH in the regulation of mood and stress, we tested the MCH1-R antagonist in several animal models of depression and anxiety. Pharmacological blockade of the MCH1-R produced a profile similar to clinically used antidepressants and anxiolytics, suggesting that the MCH1-R might be a novel target for the treatment of depression and anxiety.
ARTICLES
Melanin-concentrating hormone (MCH), a cyclic 19-aminoacid polypeptide, is produced predominantly by neurons in the lateral hypothalamus and zona incerta which project broadly throughout the brain 1 . Several lines of evidence implicate MCH as an important mediator in the regulation of energy balance and body weight. Central MCH administration stimulates food intake while fasting results in an increase in MCH expression 2 . Mice lacking the gene encoding MCH are lean, hypophagic and maintain elevated metabolic rates 3 . In contrast, mice overexpressing the MCH gene are susceptible to obesity and insulin resistance 4 . Although these findings support a rationale for MCH antagonists in the treatment of obesity, it is unclear if sufficient MCH tone exists to produce a robust and sustained loss of body weight after chronic MCH-receptor blockade. Moreover, because genetic manipulation of the MCH gene also affects the expression of neuropeptide E-I and neuropeptide G-E, which are processed from the same prehormone precursor as MCH, the observed phenotypes may be influenced by changes in the levels of these less characterized peptides 5 . The effects of MCH are mediated through receptors in the rhodopsin superfamily of G protein-coupled receptors (GPCRs). MCH1 receptor (MCH1-R) has been isolated from rodents and humans 6, 7 , whereas MCH2-R has thus far been identified only in humans 8, 9 . To assess the role of MCH1-R, we identified a selective, high-affinity MCH1-R antagonist and evaluated it in several animal models. We report here that the acute administration of a MCH1-R antagonist attenuated central MCH-stimulated food intake, and reduced consumption of palatable food. Moreover, chronic administration of this antagonist produced a robust and sustained decrease in body weight in rats with diet-induced obesity. As the distribution of MCH1-R binding sites in the central nervous system (CNS) is suggestive of a role for MCH in the regulation of mood and stress, we tested the MCH1-R antagonist in several animal models of depression and anxiety. Pharmacological blockade of the MCH1-R produced a profile similar to clinically used antidepressants and anxiolytics, suggesting that the MCH1-R might be a novel target for the treatment of depression and anxiety.
SNAP-7941 is a selective, high-affinity MCH1-R antagonist
Screening of our GPCR-biased compound collection against the human MCH1-R in a functional assay measuring intracellular Ca 2+ mobilization resulted in the discovery of a highpotency antagonist, SNAP-7941 (Fig. 1a) . SNAP-7941 is a competitive antagonist of MCH in a [
3 H]phosphoinositide accumulation assay in a mammalian cell line expressing the human MCH1-R (Fig. 1b) . The Schild regression from these data estimated a pA 2 of 9.24 with a slope of 0.98 (r 2 = 0.94) for SNAP-7941 (Fig. 1b, inset ), which predicts a K b of 0.57 nM. This compound was greater than 1,000-fold selective for MCH1-R compared with the human MCH2-R, as well as GPCRs associated with food intake including 5-HT 2c , galanin and neuropeptide Y (NPY). SNAP-7941 also proved to be suitable for use as a tritiated radioligand. Analysis of saturation isotherms revealed a measured K d of 0.18 nM with specific binding of 98% in COS-7 cells expressing human MCH1-R (Fig. 1c) 10 , suggesting that SNAP-7941 binds selectively to MCH1-R.
SNAP-7941 is a centrally active anorectic compound
To determine if the orexigenic effect of MCH is mediated by MCH1-R, we tested the effect of SNAP-7941 on MCH-stimulated food intake in rats. Systemic pretreatment with SNAP-7941 (10 mg/kg, i.p.) inhibited the increase in food intake elicited by MCH (3 nmol) injected into the third ventricle (Fig. 3a) . Although this finding supports a role for central MCH1-Rs in mediating MCH-stimulated food intake, it is not known if pharmacological blockade of MCH receptors would alter basal body weight. To test this hypothesis, SNAP-7941 was administered twice a day for seven days to rats with free access to standard lab chow. Although all rats gained weight over the course of the study, rats treated with 10 mg/kg i.p. of SNAP-7941 gained 26% less weight compared with vehicle-treated rats (Fig. 3b) . Thus, chronic pharmacological treatment with an MCH1-R antagonist decreases body weight gain in young growing rats.
MCH1-R blockade decreases palatable food consumption
As MCH affects both food intake and metabolism, the observed change in body weight following MCH1-R antagonist treatment could be attributed to a reduction in food consumption, an increase in metabolic rate or both. To evaluate the ef- 
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fect of MCH1-R blockade on palatable food consumption, we tested the effect of SNAP-7941 on the drinking of sweetened condensed milk in satiated rats. In this model, 3 mg/kg of Dfenfluramine almost completely suppressed milk consumption ( Fig. 3c ). Acute administration of SNAP-7941 produced a dose-dependent decrease in milk consumption (Fig. 3c ). Rats treated with 3, 10 and 30 mg/kg of SNAP-7941 intraperitoneally (i.p.) consumed 13, 41 and 59% less milk, respectively, than vehicle-treated rats. These results suggest that SNAP-7941 acts as an anorectic agent capable of decreasing consumption of palatable food. To test if the anorectic effect of SNAP-7941 was the result of malaise, we performed a conditioned taste aversion study. Neither SNAP-7941 (10 mg/kg, i.p.) nor vehicle changed the preference to drink a sweetened solution, whereas LiCl (300 mg/kg, i.p.) elicited a robust taste aversion effect (Fig. 3d ). This observation demonstrates that the anorectic effect of SNAP-7941 is not the result of malaise.
Effects of MCH1-R chronic blockade on diet-induced obesity
Human obesity is associated with a difficulty in balancing food consumption in the presence of excess availability of highly palatable foods, and a decrease in physical activity. To further assess the therapeutic potential of an MCH1-R antagonist in the management of human obesity, we tested the effects of SNAP-7941 in diet-induced obese (DIO) rats. Long-Evans rats were rendered obese by ad libitum exposure to a high-fat diet (45% of calories from fat). After 11 weeks, these rats weighed 592.2 ± 9.3 g (from a starting weight of 227 ± 3.2 g), whereas rats fed a control diet (10% fat) weighed 481.8 ± 14.2 g (from a starting weight of 224.7 ± 5.8 g). For a 4-week period beginning in week 12, DIO rats, maintained on the high-fat diet, were injected i.p. twice daily with either 10 mg/kg SNAP-7941, 3 mg/kg D-fenfluramine or vehicle. Whereas vehicle-treated rats ate consistently and continued to gain weight, rats treated with D-fenfluramine initially ate very little food and lost weight but then gradually increased their consumption and gained weight at a rate somewhat less than that of vehicle-treated controls ( Fig. 4a and b) . By the end of the study, D-fenfluramine-treated rats weighed 14% less than vehicle-treated rats (572.2 ± 16.5 g versus 666.4 ± 22.5 g, respectively). In contrast, rats treated with SNAP-7941 continuously ate less and lost weight throughout the duration of treatment. At the end of the 4-week treatment period, the SNAP-7941 -treated rats weighed 26% less than vehicle-treated rats (492.3 ± 15.7 g versus 666.4 ± 22.5 g, respectively). Whereas acute treatment with D-fenfluramine had a more pronounced effect than SNAP-7941 on sweetened condensed milk or high-fat food consumption, chronic treatment with SNAP-7941, but not D-fenfluramine, produced a sustained and consistent decrease in food consumption and body weight. The reversibility of the effects of both D-fenfluramine and SNAP-7941 on food intake became evident in the two weeks following the termination of drug treatment. DIO rats previously treated with SNAP-7941 showed an increase in their symbol represents mean ± s.e.m; all groups n = 7. **, P < 0.05; ***, P < 0.01, significantly lower than vehicle. c, Effect of SNAP-7941 (3 mg/kg, n = 5; 10 mg/kg, n = 7; or 30 mg/kg, n = 6), D-fenfluramine (3 mg/kg, n = 7) or vehicle (n = 6) on sweetened condensed milk consumption in rats. *, P < 0.05; ***, P < 0.01, significantly lower than vehicle. d, Effects of SNAP-7941 (10 mg/kg i.p., n = 10), LiCl (300 mg/kg i.p., n = 10) and vehicle (n = 10) on conditioned taste aversion in rats (, water; í, saccharin). **, P < 0.01, significantly different from vehicle. ARTICLES weight gain and their food consumption became indistinguishable to that seen in controls ( Fig. 4a  and b) , consistent with a tonic stimulatory role of MCH in the homeostasis of energy balance and body weight. In a separate study, the continuous infusion of SNAP-7941 at 10 mg/kg/day for 2 weeks to rats did not modify a panel of blood tests for hepatic and renal function (data not shown), ruling out toxic effects of this MCH1-R antagonist as a causal role for the reduction in weight gain and food intake.
Antidepressant and anxiolytic properties of SNAP-7941
Although MCH has been studied most extensively in relation to food intake and body weight, the distribution of MCH1-R immunoreactivity 10 and [
3 H]SNAP-7941 binding sites in areas such as the amygdala, accumbens nucleus, dorsal raphe and locus coeruleus suggest a possible role for MCH in mood regulation and anxiety. To further investigate this, SNAP-7941 was evaluated in three behavioral paradigms predictive of antidepressant and/or anxiolytic activity. Clinically used antidepressants decrease the amount of time mice or rats spend immobile in the forced-swim test 11, 12 . Pretreatment of rats with a single oral dose of SNAP-7941 (3, 10 or 30 mg/kg) or fluoxetine (10 mg/kg) significantly decreased the duration of immobility compared with vehicletreated controls, and increased the time these animals spent swimming (Fig. 5a ). The profile of SNAP-7941 in the rat forced-swim test is similar to that of clinically used antidepressants, indicating that MCH1-R receptor blockade may be a novel therapeutic modality for the treatment of depressive disorders.
The rat social-interaction test has been used as a model of social anxiety with ethological validity 13, 14 . The degree of social behavior displayed by unfamiliar male rats when placed together in a neutral territory is influenced by the perceived level of anxiety, and can be enhanced by pretreatment with anxiolytics such as chlordiazepoxide 13, 15 . Acute treatment with 3, 10 or 30 mg/kg SNAP-7941 or 5 mg/kg chlordiazepoxide significantly increased social interaction time compared with vehicle-treated controls without an overall increase in locomotor activity ( Table 1) . The response to the two lower doses of SNAP-7941 was as robust as the response to 5 mg/kg chlordiazepoxide. In comparison, the antidepressant/anxiolytic paroxetine has been reported to increase social interaction in rats following chronic but not acute treatment 15 . The profile of SNAP-7941 in the rat social-interaction test suggests that it may have anxiolytic activity as robust and as potent as chlordiazepoxide and with a more rapid onset of action than paroxetine.
Guinea pig pups separated from their mothers emit high frequency vocalizations that can be reduced by pretreatment with clinically active anxiolytics and antidepressants [16] [17] [18] . This model is an attractive complement to the two previous behavioral models because it relies on a decrease in stress-induced activity (vocalization) as opposed to an increase in overt behavioral activity (swimming or interaction). Acute treatment with 10 or 30 mg/kg SNAP-7941 or 2 mg/kg buspirone significantly reduced the number of vocalizations by guinea pig pups during a 5-minute separation from their mother (Fig. 5b) . The responses to the two higher doses of SNAP-7941 were as robust as the response to buspirone. The general locomotor status of pups, as assessed by the righting reflex and the inclined board test, was determined to be similar to control animals (data not shown).
Discussion
We have discovered a highly selective and potent MCH1-R antagonist and used it to study the behavioral effects of pharmacological antagonism of the MCH1-R. The robust and sustained decrease in food intake and body weight in normal as well as diet-induced obese rats following treatment with SNAP-7941 supports previous evidence of a role for MCH in the regulation of body weight. Moreover, it demonstrates that there is sufficient MCH drive in mammals, without apparent compensatory mechanisms, to render MCH1-R a viable target for the treatment of obesity. The robust decrease in palatable food intake along with the distribution of MCH1-R in the limbic system suggest that the anorectic effects of an MCH1-R antagonist may be mediated by both direct hypothalamic inputs and a motivational component influencing the hedonic aspect of eating. Our data, although internally consistent, cannot rule out a contribution of increased energy expenditure on the reduction of body weight observed after MCH1-R blockade. The evidence that MCH increases the synthesis and secretion of leptin by adipocytes 19 suggests the existence of additional inputs mediated by MCH receptors into the regulation of food intake and energy balance. However, the role of leptin is complex, as it might have a permissive role on the central actions of MCH by increasing the expression of MCH1-R in the hypothalamus 20 . Further studies of these questions, as well as the metabolic and hormonal changes after chronic Data are expressed as mean ± s.e.m. Significantly different from vehicle: *, P < 0.05; **, P < 0.01; n = 10 for all groups.
a b ARTICLES blockade of MCH1-R, will yield insight into the potential of this therapeutic approach in reversing the pathophysiological consequences of obesity. The convergence of positive results for SNAP-7941 in three qualitatively different models for depression/anxiety and in two different species provides strong support for a role for MCH in the regulation of mood. Our present findings are in agreement with the anxiogenic effects of MCH infusion to the medial preoptic area in rats 21 , and appear to contradict another report demonstrating an anxiolytic response to novelty following intracerebroventricular injection of MCH (ref. 22) . A possible explanation for this discrepancy is the heterogeneous distribution in the brain of exogenously applied MCH. Although the role of MCH in human psychiatric disorders remains largely unknown, we demonstrate for the first time the potential use of MCH1-R antagonists in the treatment of depression and/or anxiety. were housed individually and maintained on 12-h light/dark cycle with lights on at 06:00, and given free access to standard rat chow (Purina Mills, Saint Louis, Missouri) and water. Stainless steel cannulae were implanted stereotaxically and aimed at the third ventricle under general anesthesia, 10 d before behavioral testing. Animals were habituated to the testing paradigm, pre-tested for two consecutive days by injecting 5 µl artificial CSF into the cannula, and the amount of food consumed assessed after 30, 60 and 120 min. SNAP-7941 or its vehicle (1% DMSO) was injected i.p. 10 min prior to 3 rd ventricle injection of MCH or its vehicle (5 µl artificial CSF). This study was performed at the Department of Psychology, at Queens College (CUNY, New York), under a protocol approved by the Queens College Institutional Animal Care and Use Committee.
Methods
7-day body-weight study. Male Long-Evans rats (180-200 g at start of experiment, Charles River) were housed in groups of 4, maintained on 12-h light/dark cycle with lights on at 06:00, and given free access to standard rat chow (#5012; fat percentage, 10% kcal; Purina Mills) and water. SNAP-7941 or vehicle (0.01% lactic acid, pH 6; 1 ml/kg) was administered i.p. 2 h after lights on and 1 h before lights out.
Sweetened condensed milk study. Male Sprague-Dawley rats (180-200 g, Charles River) were housed as above. For 20 min a day (2-5 h into the light cycle) for 7 d, rats were placed in individual cages and allowed to drink sweetened condensed milk (Nestle, Glendale, California, diluted 1:3 with water). On the test day, rats received SNAP-7941, D-fenfluramine or vehicle (0.01% lactic acid (pH 6); 1 ml/kg) was administered i.p. 30 min before having access to milk. The amount of milk consumed was compared with the baseline consumption for each rat determined on the previous 3 d. corrected comparisons. For the 1- (Fig. 3b) and 4-week (Fig. 4a and b) body-weight experiments, overall results were analyzed by 2-way ANOVA, and data for each time-point were analyzed by one-way ANOVA followed by post hoc Student-Newman-Keuls test. For the sweetened condensed milk study (Fig. 3c) , swim test (Fig. 5a ), social interaction (Table 1) and maternal separation studies (Fig. 5b ), data were analyzed by one-way ANOVA followed by post hoc Student-Newman-Keuls or Fisher's LSD test.
